6th Pharma Pricing and Reimbursement Forum

Topics

• Can Price Transparency Contribute to More Affordable Patient Access to Medicines?
• How can RWE support Market Access team(s) in a post COVID landscape
• Equal access and multi-indication medicines
• International pricing references in the world of different national expenditure on drugs and healthcare, impact on patients access
• Reaching a better integration of regulatory pathways

Who should Attend

• Payers and policy makers
• Pharmaceutical companies
• Vice Presidents
• Non-industry stakeholders: Senior Vice Presidents
• Directors
• Heads
• Managers of: Pricing and Reimbursement
• Senior managers
• Commercial Pricing
• Market Access
• Health Economics
• Pricing Strategists
• Regulatory Affairs
• Outcome Research
• Public Affairs
• Governmental Affairs
• Health Outcome
• Health Policy
• Public Policy
• HTA
• Regulatory Bodies
• Governmental